United States · Venture startup

Who invested in Slate Bio

One round we have observed, with the one investor named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$2.8Mraised across 1 round since 2023, from 1 source

Latest round
Venture, $2.8MJan 2023
Investors
1
See who backed them

The rounds

  1. Jan 2023
    Venture$2.8M

    Source recordedSEC filing: $1.3M sold, first sale Dec 2022

Founders and team

From the SEC filings it signed: 2 on the team.

  • Andrew KrouseExecutive Officer, Directori
  • Kurt WoerpelExecutive Officeri

On the board, as filediBrian GallagherKyparissia SirinakisRobert Creeden

Everyone who backed them

Missing a round, or an investor who was in one? Tell us.

Also claim to have backed them

These 5 firms list Slate Bio as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.

Epidarex CapitalVC firmPer its own site
CAV Angel NetworkAngel networkPer its own site
VTC VenturesVC firmPer its own site

Quick answers about Slate Bio

Who invested in Slate Bio?

Slate Bio's investors include Virginia Innovation Partnership Corporation.

How much has Slate Bio raised?

Slate Bio has raised $2.8M across 1 round since 2023.

When did Slate Bio last raise?

Slate Bio's most recent round was a Venture of $2.8M in Jan 2023.

What was Slate Bio's biggest round?

Its most recent round, $2.8M in Jan 2023, is also its largest on record.

Who backed Slate Bio first?

Slate Bio's first round on record, in Jan 2023, was backed by Virginia Innovation Partnership Corporation.

What stage is Slate Bio at?

Slate Bio's latest named round is a Venture, in Jan 2023.

Where is Slate Bio based?

Slate Bio is based in the United States.

Companies like Slate Bio

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.